Webinar: Implementation of Gabapentin as an NSC-ADID Tier I Drug
Sponsored by
SOFT/AAFS Drugs and Driving Committee
Workshop Chairs
Kristin Kahl and Ayako Chan-Hosokawa
Date
Thursday, May 22, 2025 (available on-demand 24 hours after the conclusion of the webinar)
Time
10:00 am-12:30 pm Pacific/1:00 pm-3:30 pm Eastern
Abstract
This webinar provides a comprehensive overview of gabapentin, focusing on analytical methods, pharmacology, case examples, trends, and its reclassification as a Tier I drug in testing recommendations. The session will begin with a review of the NSC-ADID survey, highlighting the rationale behind gabapentin's upgrade from Tier II to Tier I. Attendees will gain valuable insights into various testing approaches to ensure compliance with updated recommendations. Additionally, the webinar will explore the pharmacology and behavioral effects of gabapentin, and its role in polysubstance use, emphasizing its implications for impaired driving cases. Case reports will underscore the forensic relevance of gabapentin detection, offering practical insights into interpretation and reporting. This webinar will serve as an essential resource for forensic toxicologists seeking to stay informed about the best practices in the investigation of suspected drug-impaired driving cases and motor vehicle fatalities.
Learning Objectives
- Review the updated NSC-ADID recommendations regarding gabapentin's reclassification and understand the key action items for implementation
- Develop expertise in gabapentin detection and confirmation methods and improve laboratory capabilities to align with updated recommendations
- Explore the pharmacological and behavioral effects of gabapentin, particularly in polysubstance use and impaired driving, using case reports for interpretation and reporting
Schedule (PDT)
10:00-10:10 am
NSC-ADID Survey and Gabapentin Update
Kristin Kahl
Toxicologist 3 (Supervisor)
University of Miami Toxicology Laboratory
10:10-10:30 am
Analytical Methods – Oral Fluid Screen/Quant
Cindy Coulter
Director of Laboratory Operations
9 Delta Analytical
10:30-10:50 am
Screen and Confirmation of Gabapentin by LC-QToF
Kayla Neuman
Director of Forensic Toxicology
Wisconsin State Laboratory of Hygiene
10:50-11:05 am
Break
11:05-11:35 am
Quantitation of Gabapentin by LC-MS/MS
Sara K. Dempsey
Chief of Forensic Chemistry
Dallas County Southwestern Institute of Forensic Sciences
11:35-11:55 am
Gabapentin Pharmacology
Erin Karschner
Forensic Toxicologist
Armed Forces Medical Examiner System
11:55 am-12:15 pm
Gabapentin in Impaired Driving: Trends and Case Insights
Ayako Chan-Hosokawa
Toxicology Team Manager
NMS Labs
12:15-12:30 pm
Q&A
All Speakers
|
